Skip to content
2000
image of Identification of Microvascular Invasion-Related Biomarkers for Personalized Treatment of Hepatocellular Carcinoma

Abstract

Introduction

Hepatocellular Carcinoma (HCC) exhibits high recurrence rates, particularly when accompanied by Microvascular Invasion (MVI). We identified MVI-related biomarkers and established a prognostic model for personalized HCC treatment.

Methods

Data were downloaded from The Cancer Genome Atlas (TCGA) and HCCDB databases. Key radiomics features were identified using the support vector machine-recursive feature elimination (SVM-RFE) algorithm, and differential expression analysis was performed with DESeq2. This was followed by functional enrichment analysis using the clusterProfiler package. Through univariate and Lasso regression analyses, we constructed a robust RiskScore model to effectively stratify HCC patients into distinct risk groups based on the median RiskScore value. The model prediction performance was evaluated using ROC curves and Kaplan-Meier (KM) analysis. We used the CIBERSORT algorithm to characterize immune cell infiltration patterns and conducted GSEA to identify differentially activated pathways between the risk groups.

Results

Radiomic analysis revealed four significant features strongly associated with MVI, enabling the construction of a nomogram model with robust classification performance (AUC = 0.742). Subsequent analysis identified 241 overlapping MVI-related Differentially Expressed Genes (DEGs) enriched in critical tumor proliferation and invasion pathways. A 10-gene RiskScore model was developed, demonstrating excellent prognostic discrimination in training and validation cohorts. CIBERSORT analysis revealed significant correlations between specific immune cell infiltration and the 10 genes. GSEA analysis showed significant enrichment of cell cycle regulation pathways in the high-risk group, suggesting their important role in MVI.

Discussion

The RiskScore was established using MVI-related features for prognosis assessment in HCC.

Conclusion

Our findings provided novel biomarkers and a theoretical basis for the early diagnosis and personalized treatment of HCC.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cmc/10.2174/0109298673421660250922113033
2025-10-01
2025-11-04

  • From This Site

    /content/journals/cmc/10.2174/0109298673421660250922113033
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Chandarana C.V. Mithani N.T. Singh D.V. Kikani U.B. Vibrational spectrophotometry: A comprehensive review on the diagnosis of gastric and liver cancer. Curr. Pharm. Anal. 2024 20 7 453 465 10.2174/0115734129322567240821052326
    [Google Scholar]
  2. Tang J. Zhu C. Chen Y. Wu Y. He M. Zhou Y. Xie M. Identification prognostic features related to sphingolipid metabolism and experimental validation of TRIM47 in hepatocellular carcinoma. Biocell 2024 48 4 639 651 10.32604/biocell.2024.047562
    [Google Scholar]
  3. Sung H. Ferlay J. Siegel R.L. Laversanne M. Soerjomataram I. Jemal A. Bray F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2021 71 3 209 249 10.3322/caac.21660 33538338
    [Google Scholar]
  4. Mu R. Chang M. Feng C. Cui Y. Li T. Liu C. Wang Y. Guo X. Analysis of the expression of PRDX6 in patients with Hepatocellular carcinoma and its effect on the phenotype of hepatocellular carcinoma cells. Curr. Genomics 2024 25 1 2 11 10.2174/0113892029273682240111052317 38544826
    [Google Scholar]
  5. Xu W. Liao S. Hu Y. Huang Y. Zhou J. Upregulation of miR-3130-5p enhances Hepatocellular carcinoma growth by suppressing ferredoxin 1 : miR-3130-5p Enhances HCC Growth via Inhibiting FDX1. Curr. Mol. Pharmacol. 2025 17 17 10.2174/0118761429358008250305070518 40103455
    [Google Scholar]
  6. Banerjee S. Wang D.S. Kim H.J. Sirlin C.B. Chan M.G. Korn R.L. Rutman A.M. Siripongsakun S. Lu D. Imanbayev G. Kuo M.D. A computed tomography radiogenomic biomarker predicts microvascular invasion and clinical outcomes in hepatocellular carcinoma. Hepatology 2015 62 3 792 800 10.1002/hep.27877 25930992
    [Google Scholar]
  7. Finn R.S. Qin S. Ikeda M. Galle P.R. Ducreux M. Kim T.Y. Kudo M. Breder V. Merle P. Kaseb A.O. Li D. Verret W. Xu D.Z. Hernandez S. Liu J. Huang C. Mulla S. Wang Y. Lim H.Y. Zhu A.X. Cheng A.L. IMbrave150 investigators Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N. Engl. J. Med. 2020 382 20 1894 1905 10.1056/NEJMoa1915745 32402160
    [Google Scholar]
  8. Sangro B. Chan S.L. Kelley R.K. Lau G. Kudo M. Sukeepaisarnjaroen W. Yarchoan M. De Toni E.N. Furuse J. Kang Y.K. Galle P.R. Rimassa L. Heurgué A. Tam V.C. Van Dao T. Thungappa S.C. Breder V. Ostapenko Y. Reig M. Makowsky M. Paskow M.J. Gupta C. Kurland J.F. Negro A. Abou-Alfa G.K. Azevedo S. Braghiroli M.I. Girotto G. Bragagnoli A. Branco R. Faccio A. Moretto A. Skare N. Dutra J. Viola L. Vianna K. Meton F. Sette C. Faulhaber A. Tam V.C. Couture F. Biagi J. Castel H. Mulder K. Ko Y-J. Zbuk K. Welch S. Beaudoin A. Heurgué A. Assenat E. Archambeaud I. Tougeron D. Peron J-M. Gilabert M. Bronowicki J-P. Cattan S. Blanc J-F. Bouattour M. Phelip J-M. Boige V. Michel P. Frin A-C. De Toni E.N. Berres M-L. Vogel A. Berg T. Ettrich T. Waldschmidt D. Wedemeyer H.H. Worns M-A. Bitzer M. Weiss K-H. Lau G. Chan S.L. Yau T. Tai Y.P. Lee A.S. Thungappa S.C. N L.K. Sureshchand Ostwal V. Ashok K.K. Mittal S. Goyal H. Srinivasan S. Biswas G. Mohan M. Limaye S. Asarawala N. Rimassa L. Falcone A. Gianni L. Gasbarrini A. Daniele B. Avallone A. Paolo Frassineti G.L. Roila F. Kudo M. Kawaoka T. Morimoto M. Takikawa Y. Kato N. Yamashita T. Osaki Y. Motomura K. Tateishi R. Ohkawa K. Wada Y. Onishi H. Sasahira N. Inaba Y. Kurosaki M. Tsuji K. Takei Y. Aramaki T. Hagihara A. Furuse J. Kioka K. Koga H. Sasaki Y. Numata K. Tada T. Kawaguchi Y. Nadano S. Vasilyev A. Breder V. Lipatov O. Dvorkin M. Zarubenkov O. Kutukova S. Ponomarev R. Shostka K. Alyasova A. Topuzov E. Severtsev A. Petrov Y. Erygin D. Berdov B. Kang Y-K. Tak W-Y. Park J-W. Lim H.Y. Heo J. Kim J.H. Kim T-Y. Choi H.J. Varela M. Reig Monzon M.E. Sangro B. Martin C.G. Ponce C.G. López C. Cheng A-L. Chao Y. Feng Y-H. Jeng L-B. Hung C-H. Hou M-M. Wang Tsang-En Wang J-H. Yen C-J. Sukeepaisarnjaroen W. Sunpaweravong P. Charoentum C. Tanasanvimon S. Sirachainan E. Ungtrakul T. Prasongsook N. Maneenil K. Jitpewngarm W. Ostapenko Y. Skoryi D. Bondarenko I. Shparyk Y. Trukhin D. Hotko Y. Ursol G. Kryzhanivska A. Abou-Alfa G.K. Mody K. Dayyani F. Al-Rajabi R. Yarchoan M. Gandhi S. Crysler O. He A.R. Reeves J. Bahary N. Mahipal A. Kelley R.K. Dasgupta A. Rowe J. Thota R. Beg M. Morse M. Choi S. Crocenzi T. Somer B. Abrams T. Denlinger C. Zhang Y. Sharma N. Dao T.V. Thinh N.T. Tuyet Phuong L.T. HIMALAYA investigators Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. Ann. Oncol. 2024 35 5 448 457 10.1016/j.annonc.2024.02.005 38382875
    [Google Scholar]
  9. Kudo M. Finn R.S. Qin S. Han K.H. Ikeda K. Piscaglia F. Baron A. Park J.W. Han G. Jassem J. Blanc J.F. Vogel A. Komov D. Evans T.R.J. Lopez C. Dutcus C. Guo M. Saito K. Kraljevic S. Tamai T. Ren M. Cheng A.L. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial. Lancet 2018 391 10126 1163 1173 10.1016/S0140‑6736(18)30207‑1 29433850
    [Google Scholar]
  10. Ye L. Yang X. Guo E. Chen W. Lu L. Wang Y. Peng X. Yan T. Zhou F. Liu Z. Sorafenib metabolism is significantly altered in the liver tumor tissue of hepatocellular carcinoma patient. PLoS One 2014 9 5 e96664 10.1371/journal.pone.0096664 24797816
    [Google Scholar]
  11. Noda S. Shioya M. Hira D. Fujiyama Y. Morita S. Terada T. Pharmacokinetic interaction between sorafenib and prednisolone in a patient with hepatocellular carcinoma. Cancer Chemother. Pharmacol. 2013 72 1 269 272 10.1007/s00280‑013‑2187‑9 23673446
    [Google Scholar]
  12. Suchman K. Da B.L. Letter to the editor: A reminder to screen for varices! Atezolizumab/bevacizumab for HCC. Hepatology 2022 76 4 E78 E79 10.1002/hep.32556 35503724
    [Google Scholar]
  13. Galle P.R. Forner A. Llovet J.M. Mazzaferro V. Piscaglia F. Raoul J-L. Schirmacher P. Vilgrain V. European association for the study of the liver Management of hepatocellular carcinoma. J. Hepatol. 2018 69 1 182 236 10.1016/j.jhep.2018.03.019 29628281
    [Google Scholar]
  14. Erstad D.J. Tanabe K.K. Prognostic and therapeutic implications of microvascular invasion in Hepatocellular Carcinoma. Ann. Surg. Oncol. 2019 26 5 1474 1493 10.1245/s10434‑019‑07227‑9 30788629
    [Google Scholar]
  15. Beaufrère A. Caruso S. Calderaro J. Poté N. Bijot J.C. Couchy G. Cauchy F. Vilgrain V. Zucman-Rossi J. Paradis V. Gene expression signature as a surrogate marker of microvascular invasion on routine hepatocellular carcinoma biopsies. J. Hepatol. 2022 76 2 343 352 10.1016/j.jhep.2021.09.034 34624411
    [Google Scholar]
  16. Erstad D.J. Tanabe K.K. Scoring microvascular invasion in hepatocellular carcinoma: Are we meeting the grade? Hepatobiliary Surg. Nutr. 2024 13 1 184 187 10.21037/hbsn‑23‑50 38322216
    [Google Scholar]
  17. Uylas U. Tolan H.K. Ince V. Kayaalp C. Yilmaz S. Living donor liver transplantation for hepatocellular carcinoma with bile duct tumor thrombi. J. Gastrointest. Cancer 2018 49 4 510 512 10.1007/s12029‑017‑9935‑8 28353162
    [Google Scholar]
  18. Roayaie S. Blume I.N. Thung S.N. Guido M. Fiel M.I. Hiotis S. Labow D.M. Llovet J.M. Schwartz M.E. A system of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma. Gastroenterology 2009 137 3 850 855 10.1053/j.gastro.2009.06.003 19524573
    [Google Scholar]
  19. Lv K. Cao X. Du P. Fu J.Y. Geng D.Y. Zhang J. Radiomics for the detection of microvascular invasion in hepatocellular carcinoma. World J. Gastroenterol. 2022 28 20 2176 2183 10.3748/wjg.v28.i20.2176 35721882
    [Google Scholar]
  20. Bera K. Braman N. Gupta A. Velcheti V. Madabhushi A. Predicting cancer outcomes with radiomics and artificial intelligence in radiology. Nat. Rev. Clin. Oncol. 2022 19 2 132 146 10.1038/s41571‑021‑00560‑7 34663898
    [Google Scholar]
  21. Zhang W. Yang R. Liang F. Liu G. Chen A. Wu H. Lai S. Ding W. Wei X. Zhen X. Jiang X. Prediction of microvascular invasion in hepatocellular carcinoma with a multi-disciplinary team-like radiomics fusion model on dynamic contrast-enhanced computed tomography. Front. Oncol. 2021 11 660629 10.3389/fonc.2021.660629 33796471
    [Google Scholar]
  22. Zhang X. Ruan S. Xiao W. Shao J. Tian W. Liu W. Zhang Z. Wan D. Huang J. Huang Q. Yang Y. Yang H. Ding Y. Liang W. Bai X. Liang T. Contrast-enhanced CT radiomics for preoperative evaluation of microvascular invasion in hepatocellular carcinoma: A two-center study. Clin. Transl. Med. 2020 10 2 e111 10.1002/ctm2.111 32567245
    [Google Scholar]
  23. Chen Y. Meng Z. Zhang Y. Xiang Z. Natural killer cell-associated radiogenomics model for hepatocellular carcinoma: Integrating CD2 and enhanced CT-derived radiomics signatures. Acad. Radiol. 2025 32 4 1981 1992 10.1016/j.acra.2024.10.043 39542805
    [Google Scholar]
  24. Zhang Z. Wang S. Zhu Z. Nie B. Identification of potential feature genes in non-alcoholic fatty liver disease using bioinformatics analysis and machine learning strategies. Comput. Biol. Med. 2023 157 106724 10.1016/j.compbiomed.2023.106724 36898287
    [Google Scholar]
  25. Song Z. Yu J. Wang M. Shen W. Wang C. Lu T. Shan G. Dong G. Wang Y. Zhao J. CHDTEPDB: Transcriptome expression profile database and interactive analysis platform for congenital heart disease. Congenit. Heart Dis. 2023 18 6 693 701 10.32604/chd.2024.048081
    [Google Scholar]
  26. Yu G. Wang L.G. Han Y. He Q.Y. clusterProfiler: An R package for comparing biological themes among gene clusters. OMICS 2012 16 5 284 287 10.1089/omi.2011.0118 22455463
    [Google Scholar]
  27. Wang S. Xie C. Hu H. Yu P. Zhong H. Wang Y. Shan L. iTRAQ-based proteomic analysis unveils ncam1 as a novel regulator in doxorubicin-induced cardiotoxicity and DT-010-exerted cardioprotection. Curr. Pharm. Anal. 2025 20 9 966 977 10.2174/0115734129331758241022113026
    [Google Scholar]
  28. Ma X. Mo C. Huang L. Cao P. Shen L. Gui C. Robust rank aggregation and least absolute shrinkage and selection operator analysis of novel gene signatures in dilated cardiomyopathy. Front. Cardiovasc. Med. 2021 8 747803 10.3389/fcvm.2021.747803 34970603
    [Google Scholar]
  29. Li C. Zhang T. Yan M. Chen Y. Nan R. Chen J. Wang X. Exploring genes within the glutathione peroxidase family as potential predictors of prognosis in papillary renal cell carcinoma. Oncologie 2024 26 4 633 641 10.1515/oncologie‑2024‑0056
    [Google Scholar]
  30. Zhao X. Zhang L. Wang J. Zhang M. Song Z. Ni B. You Y. Identification of key biomarkers and immune infiltration in systemic lupus erythematosus by integrated bioinformatics analysis. J. Transl. Med. 2021 19 1 35 10.1186/s12967‑020‑02698‑x 33468161
    [Google Scholar]
  31. Xu L. Zeng Y. Li W. Zeng X. Zhong G. Chen J. Wang L. Xu M. Zeng Q. Novel hypoxia-related biomarkers and targeted drugs for acute myocardial infarction revealed by bioinformatics. Lett. Drug Des. Discov. 2024 21 18 4529 4543 10.2174/0115701808357619241218071056
    [Google Scholar]
  32. Chen D. Xu L. Xing H. Shen W. Song Z. Li H. Zhu X. Li X. Wu L. Jiao H. Li S. Yan J. He Y. Yan D. Sangerbox 2: Enhanced functionalities and update for a comprehensive clinical bioinformatics data analysis platform. iMeta 2024 3 5 e238 10.1002/imt2.238 39429873
    [Google Scholar]
  33. Han X. Shan L. Xu R. Zhou J. Lu M. Assessing MRI-based artificial intelligence models for preoperative prediction of microvascular invasion in hepatocellular carcinoma: A systematic review and meta-analysis. Acad. Radiol. 2025 10.1016/j.acra.2025.06.030 40670226
    [Google Scholar]
  34. Sun Z. Gao B. Song L. Wang B. Li J. Jiang H. Li X. Yu Y. Zhou Z. Yang Z. Sun X. Jiao T. Zhao X. Lu S. Jiao S. Single-cell RNA sequencing reveals intratumoral heterogeneity and multicellular community in primary hepatocellular carcinoma underlying microvascular invasion. Heliyon 2024 10 18 e37233 10.1016/j.heliyon.2024.e37233 39309949
    [Google Scholar]
  35. Lindskrog S.V. Prip F. Lamy P. Taber A. Groeneveld C.S. Birkenkamp-Demtröder K. Jensen J.B. Strandgaard T. Nordentoft I. Christensen E. Sokac M. Birkbak N.J. Maretty L. Hermann G.G. Petersen A.C. Weyerer V. Grimm M.O. Horstmann M. Sjödahl G. Höglund M. Steiniche T. Mogensen K. de Reyniès A. Nawroth R. Jordan B. Lin X. Dragicevic D. Ward D.G. Goel A. Hurst C.D. Raman J.D. Warrick J.I. Segersten U. Sikic D. van Kessel K.E.M. Maurer T. Meeks J.J. DeGraff D.J. Bryan R.T. Knowles M.A. Simic T. Hartmann A. Zwarthoff E.C. Malmström P.U. Malats N. Real F.X. Dyrskjøt L. An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer. Nat. Commun. 2021 12 1 2301 10.1038/s41467‑021‑22465‑w 33863885
    [Google Scholar]
  36. Du W. Xia X. Gou Q. Xie Y. Gao L. Comprehensive review regarding the association of E2Fs with the prognosis and immune infiltrates in human head and neck squamous cell carcinoma. Asian J. Surg. 2024 47 5 2106 2121 10.1016/j.asjsur.2024.01.130 38320907
    [Google Scholar]
  37. Gao F. Li X. Xu K. Wang R. Guan X. c-MYC mediates the crosstalk between breast cancer cells and tumor microenvironment. Cell Commun. Signal. 2023 21 1 28 10.1186/s12964‑023‑01043‑1 36721232
    [Google Scholar]
  38. Han J. Li Z.L. Xing H. Wu H. Zhu P. Lau W.Y. Zhou Y.H. Gu W.M. Wang H. Chen T.H. Zeng Y.Y. Wu M.C. Shen F. Yang T. The impact of resection margin and microvascular invasion on long-term prognosis after curative resection of hepatocellular carcinoma: A multi-institutional study. HPB 2019 21 8 962 971 10.1016/j.hpb.2018.11.005 30718183
    [Google Scholar]
  39. Hidaka M. Eguchi S. Okuda K. Beppu T. Shirabe K. Kondo K. Takami Y. Ohta M. Shiraishi M. Ueno S. Nanashima A. Noritomi T. Kitahara K. Fujioka H. Impact of anatomical resection for hepatocellular carcinoma with microportal invasion (vp1). Ann. Surg. 2020 271 2 339 346 10.1097/SLA.0000000000002981 30048313
    [Google Scholar]
  40. Chun Y.S. Pawlik T.M. Vauthey J.N. 8th edition of the AJCC cancer staging manual: Pancreas and hepatobiliary cancers. Ann. Surg. Oncol. 2018 25 4 845 847 10.1245/s10434‑017‑6025‑x 28752469
    [Google Scholar]
  41. Gou J. Li J. Li Y. Lu M. Wang C. Zhuo Y. Dong X. The diagnostic accuracy between radiomics model and non-radiomics model for preoperative of microvascular invasion of solitary hepatocellular carcinoma: A systematic review and meta-analysis. Acad. Radiol. 2024 31 11 4419 4433 10.1016/j.acra.2024.04.003 38664142
    [Google Scholar]
  42. Pan R.G. Zhou J. Wang X.W. Cen X.K. Zhou Y.P. Guo Y.Y. Feng X.F. Prognostic implication and immunotherapy response prediction of a novel ubiquitination-related gene signature in liver cancer. Aging 2024 16 11 10142 10164 10.18632/aging.205926 38870259
    [Google Scholar]
  43. Zhang H. Jiang W. Jiang Y. Xu N. Nong L. Li T. Liu R. Investigating the therapeutic potential of hesperidin targeting CRISP2 in intervertebral disc degeneration and cancer risk mitigation. Front. Pharmacol. 2024 15 1447152 10.3389/fphar.2024.1447152 39268471
    [Google Scholar]
  44. Li Z. Chen J. Zhao S. Li Y. Zhou J. Liang J. Tang H. Discovery and validation of novel biomarkers for detection of cervical cancer. Cancer Med. 2021 10 6 2063 2074 10.1002/cam4.3799 33624385
    [Google Scholar]
  45. Xie C. Yang Z. Suo Y. Chen Q. Wei D. Weng X. Gu Z. Wei X. Systemically infused mesenchymal stem cells show different homing profiles in healthy and tumor mouse models. Stem Cells Transl. Med. 2017 6 4 1120 1131 10.1002/sctm.16‑0204 28205428
    [Google Scholar]
  46. Kuo H.C. Kuo Y.R. Lee K.F. Hsieh M.C. Huang C.Y. Hsieh Y.Y. Lee K.C. Kuo H.L. Lee L.Y. Chen W.P. Chen C.C. Tung S.Y. A Comparative proteomic analysis of erinacine A's inhibition of gastric cancer cell viability and invasiveness. Cell Physiol. Biochem. 2017 43 1 195 208 10.1159/000480338 28854418
    [Google Scholar]
  47. Xu D. Liu Y. Liu Q. Li G. Zhang L. Yu C. Liang H. Chen X. Zheng J. Song J. N6-methyladenosine modification of circular RNA circASH2L suppresses growth and metastasis in hepatocellular carcinoma through regulating hsa-miR-525-3p/MTUS2 axis. J. Transl. Med. 2024 22 1 1026 10.1186/s12967‑024‑05745‑z 39543614
    [Google Scholar]
  48. Zhang Z. Zhu J. Huang Y. Li W. Cheng H. MYO18B promotes hepatocellular carcinoma progression by activating PI3K/AKT/mTOR signaling pathway. Diagn. Pathol. 2018 13 1 85 10.1186/s13000‑018‑0763‑3 30390677
    [Google Scholar]
  49. Kang G. Hwang W.C. Do I.G. Wang K. Kang S.Y. Lee J. Park S.H. Park J.O. Kang W.K. Jang J. Choi M.G. Lee J.H. Sohn T.S. Bae J.M. Kim S. Kim M.J. Kim S. Park C.K. Kim K.M. Exome sequencing identifies early gastric carcinoma as an early stage of advanced gastric cancer. PLoS One 2013 8 12 e82770 10.1371/journal.pone.0082770 24376576
    [Google Scholar]
  50. Li R. Yan X. Zhong W. Zheng J. Li X. Liang J. Hu Z. Liu H. Chen G. Yang Y. Zhang J. Qu E. Liu W. Stratifin promotes the malignant progression of HCC via binding and hyperactivating AKT signaling. Cancer Lett. 2024 592 216761 10.1016/j.canlet.2024.216761 38490326
    [Google Scholar]
  51. Wang Y. Jin B. Wu X. Xing J. Zhang B. Chen X. Liu X. Wan X. Du S. Exploration of prognostic and treatment markers in hepatocellular carcinoma via GPCR-related genes analysis. Heliyon 2024 10 9 e29659 10.1016/j.heliyon.2024.e29659 38694033
    [Google Scholar]
  52. Barbe A. Kurowska P. Rame C. Froment P. Rak A. Dupont J. Adipolin (C1QTNF12) is a new adipokine in female reproduction: Expression and function in porcine granulosa cells. Reproduction 2023 167 1 e230272 10.1530/REP‑23‑0272 37971748
    [Google Scholar]
  53. Chen M. Yang Y. Hu G. Peng Z. Wen W. The promoting effect of the POU3F2/METTL16/PFKM cascade on glycolysis and tumorigenesis of hepatocellular carcinoma. Ann. Hepatol. 2025 30 2 101776 10.1016/j.aohep.2025.101776 39756795
    [Google Scholar]
/content/journals/cmc/10.2174/0109298673421660250922113033
Loading
Identification of Microvascular Invasion-Related Biomarkers for Personalized Treatment of Hepatocellular Carcinoma
Bentham Science Publishers ; https://doi.org/10.2174/0109298673421660250922113033
/content/journals/cmc/10.2174/0109298673421660250922113033
/content/journals/cmc/10.2174/0109298673421660250922113033
Loading

Data & Media loading...


  • Article Type:     Research Article
Keywords: immune infiltration analysis ; biomarker ; tumor microenvironment ; radiomics feature ; Hepatocellular carcinoma ; microvascular invasion

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test